TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16103233
Drug: Quartile of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartile of patients with the biggest average decrease in hemoglobin (from 14.2 to 12.6 g/dL)
Study: 11967028
Drug: Somatostatin +
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin + low dose insulin (0.1 mU/kg/min)
Study: 11967028
Drug: Somatostatin +
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin + high dose insulin (1.5 mU/kg/min)
Study: 11967028
Drug: Insulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1.5 mU/kg/min) + somatostatin
Study: 10589750
Drug: IT DepoCyt
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT DepoCyt (50 mg doses, up to six doses over 3 months)
Study: 10589750
Drug: IT methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IT methotrexate (10 mg doses, up to sixteen doses over 3 months)
Study: 1378139
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg carvedilol b.i.d.
Study: 12393768
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate 30 mg kg(‐1)
Study: 7763157
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 90 mL of saline and dextrose into the knee joint cavity
Study: 30966728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no injection)
Study: 2155569
Drug: 6‐month regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐month regimen (self‐administered isoniazid and rifampin daily for 24 weeks, plus pyrazinamide daily during the first 8 weeks)
Study: 6455969
Drug: Biotin treatment
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biotin treatment
Study: 6455969
Drug: Essential fatty
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential fatty acid treatment
Study: 22149929
Drug: Mouth rinse
Normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinse containing zinc acetate (0.3%) and chlorhexidine diacetate without adjunct tongue scraping
Study: 21381407
Drug: Probiotic (Bioflora)
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Bioflora) containing Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis, and Bifidobacterium brevis, 5 ml bid for 5 days
Study: 21381407
Drug: Metronidazol (Flagyl),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazol (Flagyl), 500 mg bid for 5 days
Study: 9665010
Drug: Prograf (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf (0.2 mg/kg per day)
Study: 9665010
Drug: Neoral (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (8 mg/kg per day)
Study: 8580802
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy (adriamycin-containing) followed by involved-field radiotherapy; chemotherapy combinations were CHOP (18 patients) and ProMACE/MOPP (8 patients).
Study: 8580802
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy (adriamycin-containing) without radiotherapy.
Study: 2635496
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 0.3 mg/kg
Study: 2635496
Drug: Intravenous thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thiopental 6.0 mg/kg
Study: 12052481
Drug: Genistein (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein (54 mg/day)
Study: 15243277
Drug: EPT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPT (1 mg 17beta‐estradiol combined with 0.5 mg norethisterone acetate)
Study: 9039174
Drug: Itraconazole, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, 200 mg twice daily for the first week of each month for 2 consecutive months
Study: 8017472
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg single dose)
Study: 3306545
Drug: Topical Healon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Healon
Study: 25506706
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine
Study: 27410770
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (room air)
Study: 15182393
Drug: GLA (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA (2.0 g/d)
Study: 15182393
Drug: STA (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA (1.0 g/d) + GLA (0.9 g/d)
Study: 20819493
Drug: NDP (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDP (40 mg/m(2)) and dexamethasone (10 mg) dissolved in 40 ml normal saline
Study: 20819493
Drug: cDDP (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: cDDP (40 mg/m(2)) and dexamethasone (10 mg) dissolved in 40 ml normal saline
Study: 18062117
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP)
Study: 18062117
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of GCF MMP-8 levels between flurbiprofen and placebo groups after therapy
Study: 15711671
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B virus vaccine administered at 2, 3, 9 months concurrently with BCG (n=20)
Study: 2782734
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled salbutamol (LDS), 800 micrograms daily
Study: 23139262
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin (50 mg/m² d1), ifosfamide (3 g/m²/day d1-2), cisplatin (75 mg/m² d3) + G-CSF every 3 weeks (arm A)
Study: 22256637
Drug: Zhizhu Kuanzhong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhu Kuanzhong capsule
Study: 25543420
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication
Study: 18438705
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg for 14 days)
Study: 18438705
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg for 14 days)
Study: 10814771
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg/day
Study: 9597411
Drug: Creatine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine 20 g daily for 5 days
Study: 8192458
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CAE) at 30 mg/kg/day for 10 days
Study: 8192458
Drug: Amoxicillin-clavulanate (AMX-CL)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (AMX-CL) at 40 mg/kg/day for 10 days
Study: 8192458
Drug: Amoxicillin-clavulanate (AMX-CL)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (AMX-CL)
Study: 26376926
Drug: Standard-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose trivalent subunit inactivated intramuscular vaccine
Study: 16918614
Drug: Glycerol ointment
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol ointment applied twice daily
Study: 9382659
Drug: β-blockers (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (including timolol maleate, propranolol hydrochloride)
Study: 9382659
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (including captopril, ramipril)
Study: 8322563
Drug: Mepivacaine 2%
Normalized name: mepivacaine 2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 2% and adrenaline 1:200,000 with crystalloid volume loading of 10 ml.kg-1 b.w.
Study: 2868656
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg twice daily for 10 weeks)
Study: 2868656
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice daily for 10 weeks)
Study: 2437789
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg)
Study: 30695290
Drug: Cariprazine (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (3, 6, or 9 mg/d)
Study: 3306508
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist
Study: 7661158
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. and amoxicillin 1 g t.i.d. (OA)
Study: 7661158
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d., amoxicillin 1 g t.i.d. plus tetracycline 500 mg t.i.d. (OAT)
Study: 2508566
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with mitomycin C (MMC) and tegafur (FT)
Study: 28712185
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg) + Propofol (Group II)
Study: 24012096
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine gel (6 mL)
Study: 21794845
Drug: 0.05% AR‐12286
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% AR‐12286 Ophthalmic Solution
Study: 21794845
Drug: 0.1% AR‐12286
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% AR‐12286 Ophthalmic Solution
Study: 21794845
Drug: 0.25% AR‐12286
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% AR‐12286 Ophthalmic Solution
Study: 7593733
Drug: Moclobemide treatment
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide treatment
Study: 29053933
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ellagic acid daily for 12 weeks
Study: 26689303
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) after initial treatment
Study: 22399019
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 12 sessions, manualized
Study: 25454802
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg eszopiclone
Study: 12006422
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled fluticasone propionate (FP), 2,000 microg/d for 8 weeks
Study: 11080405
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg IV
Study: 6354932
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg three times daily)
Study: 24557492
Drug: Propranolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol treatment (group 2)
Study: 24557492
Drug: Prepropranolol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepropranolol treatment (group 1)
Study: 20830534
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids starting within 24 h of birth, advanced to 2.5 g/kg per day by day 3
Study: 15220202
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin sensitivity and low insulin response
Study: 12469360
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) treatment
Study: 12469360
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (Control)
Study: 10099053
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ebastine (young)
Study: 10099053
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ebastine (both groups)
Study: 2594822
Drug: Both terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both terbutaline and salbutamol at highest dose
Study: 30831600
Drug: Serum ferritin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ferritin <15 μg/L
Study: 22801470
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (stretching and strengthening exercises)
Study: 12205547
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) 10 mg/24 hours adhesive patch
Study: 8729740
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN)
Study: 2183868
Drug: Atenolol (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50‐100 mg once daily)
Study: 2183868
Drug: Nitrendipine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20‐40 mg once daily)
Study: 2183868
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol (50 mg) and nitrendipine (20 mg) once daily
Study: 6258620
Drug: Isoprenaline given
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline given 30 min before paracetamol
Study: 6258620
Drug: Isoprenaline given
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline given immediately before paracetamol
Study: 27916338
Drug: Forearm band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm band worn for more than 6 hours daily for at least 6 months
Study: 19797280
Drug: Dietary intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary intervention, self-monitoring of blood glucose, and insulin therapy if necessary
Study: 2309999
Drug: Meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1 mg kg‐1)
Study: 16834791
Drug: Nalbuphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.3 mg kg‐1)
Study: 30507561
Drug: Squatting exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squatting exercise in addition to a traditional physical therapy program
Study: 30507561
Drug: Squatting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squatting with hip adduction exercise in addition to a traditional physical therapy program
Study: 20127794
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for nightmares
Study: 12177649
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol therapy (200 mg/day)
Study: 12177649
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine hydrochloride therapy (200 mg/day)
Study: 7589028
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) infusion at doses of 0.015, 0.25, 1.0, and 2.0 micrograms.kg‐1.min‐1
Study: 8092756
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline) infusion
Study: 10758467
Drug: Oral etilefrine
Normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral etilefrine 15 mg (30 drops), 60 min before the subarachnoid block
Study: 6731015
Drug: E-Z-CAT (barium
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-Z-CAT (barium sulphate suspension)
Study: 27038611
Drug: Dader method
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dader method for pharmaceutical care
Study: 19874926
Drug: Sci-B-Vac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sci-B-Vac vaccine (3 doses, 0-1-6 month scheme)
Study: 17257476
Drug: Tramadol/Acetaminophen (APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/Acetaminophen (APAP)
Study: 17448262
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill
Study: 11262515
Drug: Inositol (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (18 g)
Study: 25801408
Drug: Ivabradine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (7.5 mg b.i.d.)
Study: 26355170
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (5.0 to 8.5 mm)
Study: 26355170
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants and augmented group
Study: 23801842
Drug: Combined LAM
Normalized name: Viril Lam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined LAM and ADV therapy
Study: 23801842
Drug: LAM alone
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM alone (monotherapy)
Study: 20878425
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day mesalazine (two divided doses)
Study: 20878425
Drug: 2.25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g/day mesalazine (three divided doses)
Study: 20878425
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day mesalazine
Study: 20878425
Drug: 2.25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g/day mesalazine
Study: 12180581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 7 ml of a mixture of 2% lignocaine and hyaluronidase with 1 ml normal saline
Study: 7741773
Drug: Caroverine 80
Normalized name: caroverine
DrugBank: Caroverine (DB13835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine 80 mg orally
Study: 7741773
Drug: Caroverine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine (all doses)
Study: 7741773
Drug: Caroverine (lowest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine (lowest oral dose)
Study: 1970370
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin (initial dose 2.5 mg/kg, mean stabilisation dose 3.8 mg/kg)
Study: 30256671
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target <120 mmHg)
Study: 30256671
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure target <140 mmHg)
Study: 17116835
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone plus azathioprine
Study: 17116835
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone plus mycophenolate mofetil
Study: 21913385
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (control group)
Study: 19407274
Drug: Mixed treatment
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed treatment group
Study: 19407274
Drug: No-antipsychotic group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-antipsychotic group
Study: 17589948
Drug: OAC7 (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC7 (7-day triple therapy: omeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
Study: 17589948
Drug: OAC14 (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC14 (14-day triple therapy: omeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
Study: 17589948
Drug: OAC14 (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC14 (14-day triple therapy)
Study: 17589948
Drug: OAC7 (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC7 (7-day triple therapy)
Study: 12816908
Drug: 0.39 mg
Normalized name: tyrosine 0.39 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.39 mg THC/day
Study: 12816908
Drug: 0.47 mg
Normalized name: urea 0.47 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.47 mg THC/day
Study: 12816908
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg THC/day
Study: 12816908
Drug: 14.8 mg
Normalized name: camphor 14.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.8 mg THC/day
Study: 15107145
Drug: 0.39 to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.39 to 14.8 mg THC/day
Study: 9645714
Drug: Preenucleation radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preenucleation radiation treatment
Study: 22959881
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone phosphate 1%
Study: 17431063
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of diazepam
Study: 989400
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5653 (three doses)
Study: 26069291
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg iv/4 weeks, 12 doses)
Study: 12757447
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg
Study: 23441762
Drug: Desloratadine 10
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine 10 mg
Study: 19705620
Drug: Rapid test
Normalized name: InteliSwab Covid-19 Rapid Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid test detecting heterophil antibodies
Study: 16735654
Drug: Self-Administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administration of Medication (SAM) tool
Study: 15558387
Drug: Pe‐Lite liner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pe‐Lite liner with neoprene suspension sleeve